Evidence map›Paper›PMID 31536518›Full record

ArticlePloS one2019

Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors.

Holly Janes, Marshall D Brown, David V Glidden, Kenneth H Mayer, Susan P Buchbinder, Vanessa M McMahan, Mauro Schechter, Juan Guanira, Martin Casapia

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 3 countries.

Holly JanesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.ORCID 0000-0002-3237-984X
Marshall D BrownVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California School of Medicine, San Francisco, California, United States of America.
Kenneth H MayerDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, and The Fenway Institute, Fenway Health, Boston, Massachusetts, United States of America.
Susan P BuchbinderBridge HIV, San Francisco Department of Public Health, San Francisco, California, United States of America.
Vanessa M McMahanDepartment of Medicine, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0003-2331-7206
Mauro SchechterProjeto Praça Onze, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Juan GuaniraAsociación Civil Impacta Salud y Educación, Lima, Peru.
Martin CasapiaAsociación Civil Selva Amazónica, Iquitos, Peru.
Fred Hutch Cancer Center · USAsociación Civil Impacta Salud y Educación · PEAsociación para la Conservación de la Cuenca Amazónica · PEBeth Israel Deaconess Medical Center · USSan Francisco Department of Public Health · USUniversidade Federal do Rio de Janeiro · BRUniversity of California, San Francisco · USUniversity of Washington · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Chemoprophylaxis for HIV Prevention in Men SupplementU01AI064002 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2005 to 2011
$41.3M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Statistical Methods for Evaluating Markers for Treatment SelectionR01CA152089 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JANES, HOLLY · 2010 to 2021
$3.8M
PrEP and ART adherence monitoring using dried blood spotsU01AI106499 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ANDERSON, PETER L. · 2013 to 2016
$2.9M
Comparison of Pharmacologic Markers of Exposure to HIV Pre-Exposure ProphylaxisR03AI122908 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GLIDDEN, DAVID V. · 2016 to 2017
$159k
NCI NIH HHS R01 CA152089NIAID NIH HHS P30 AI060354NIAID NIH HHS R03 AI122908NIAID NIH HHS U01 AI064002NIAID NIH HHS U01 AI106499NIAID NIH HHS UM1 AI069496
6 · The paper itself

Abstract

introductionDeveloping guidelines to inform the use of antiretroviral pre-exposure prophylaxis (PrEP) for HIV prevention in resource-limited settings must necessarily be informed by considering the resources and infrastructure needed for PrEP delivery. We describe an approach that identifies subpopulations of cisgender men who have sex with men (MSM) and transgender women (TGW) to prioritize for the rollout of PrEP in resource-limited settings.

methodsWe use data from the iPrEx study, a multi-national phase III study of PrEP for HIV prevention in MSM/TGW, to build statistical models that identify subpopulations at high risk of HIV acquisition without PrEP, and with high expected PrEP benefit. We then evaluate empirically the population impact of policies recommending PrEP to these subpopulations, and contrast these with existing policies.

resultsA policy recommending PrEP to a high risk subpopulation of MSM/TGW reporting condomless receptive anal intercourse over the last 3 months (estimated 3.3% 1-year HIV incidence) yields an estimated 1.95% absolute reduction in 1-year HIV incidence at the population level, and 3.83% reduction over 2 years. Importantly, such a policy requires rolling PrEP out to just 59.7% of MSM/TGW in the iPrEx population. We find that this policy is identical to that which prioritizes MSM/TGW with high expected PrEP benefit. It is estimated to achieve nearly the same reduction in HIV incidence as the PrEP guideline put forth by the US Centers for Disease Control, which relies on the measurement of more behavioral risk factors and which would recommend PrEP to a larger subset of the MSM/TGW population (86% vs. 60%).

conclusionsThese findings may be used to focus future mathematical modelling studies of PrEP in resource-limited settings on prioritizing PrEP for high-risk subpopulations of MSM/TGW. The statistical approach we took could be employed to develop PrEP policies for other at-risk populations and resource-limited settings.

Indexed as

AdultAnti-Retroviral AgentsClinical Trials, Phase III as TopicFemaleHealth PolicyHealth Risk BehaviorsHIV InfectionsHomosexuality, MaleHumansMalePractice Guidelines as TopicPre-Exposure ProphylaxisRisk AssessmentRisk FactorsSocioeconomic FactorsTransgender PersonsAnti-Retroviral Agents

Identifiers

PMID31536518
PMCPMC6752862
OpenAlexW2974492182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.